Navigation Links
Masimo Introduces Pronto-7™ Internationally and Lifts Voluntary Recall
Date:8/8/2011

IRVINE, Calif., Aug. 8, 2011 /PRNewswire/ -- Masimo (NASDAQ: MASI) announced today that it has lifted the voluntary product recall the company imposed on the noninvasive finger sensor of its Pronto-7 handheld device to improve the product's performance in low ambient temperatures. The Pronto-7 and new finger sensors are pending FDA 510(k) clearance in the U.S.  

(Photo: http://photos.prnewswire.com/prnh/20110808/LA48532 )

New product features and enhancements include the addition of Max Sensitivity Mode that allows measurement over a broader range of patients.  The addition of three noninvasive sensor sizes permits the instrument to be used on a broader range of finger diameters.  Each of the new sensors is color-coded to make size identification easy (Small-Yellow, Medium-Red, and Large-White).  

Masimo Founder and CEO, Joe Kiani, stated:  "We take the integrity of our design and our promises to our customers seriously.  We worked through the recall until we had redesigned the sensor for Pronto-7 so that it would perform as intended in the broadest range of likely ambient temperatures.  We are delighted to re-introduce the Pronto-7 and with it the potential impact of noninvasive hemoglobin spot-check measurements that offer healthcare providers around the world the opportunity to transform the way and amount of time it takes to deliver the right care, at the right time to patients. We believe that Pronto-7's latest features and enhancements will help clinicians to better assess more patients and make better clinical decisions based on the availability of these quick and noninvasive hemoglobin measurements."

As part of Masimo's premarket testing and verification process, over 14,443 Pronto-7 measure
'/>"/>

SOURCE Masimo
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Masimo to Report Second Quarter 2011 Financial Results after Market Close on August 9, 2011
2. Masimo and Dartmouth-Hitchcock Medical Center, First Cross-Industry Collaborative Honored With the Institute for Technology and Healthcare Clinical Application Award
3. Masimo Announces Rainbow Agreement with Philips
4. Masimo Pronto-7 Wins GOLD in the 2011 Medical Design Excellence Award Competition—the Premier Awards Program for the Medical Technology Community
5. Masimo Initiates Limited Market Release of E1, Single-Patient-Use Ear Sensor for Pulse Oximetry Monitoring
6. Masimo to Present at Goldman Sachs 32nd Annual Global Healthcare Conference
7. Masimo Reports First Quarter 2011 Financial Results
8. Masimo Launches New Reusable SpCO® Sensor with Improved Accuracy and Reliability in Low Oxygen Saturation and Elevated Methemoglobin States
9. New Published Study Finds Masimo Noninvasive SpCO Effective for Screening Emergency Department Patients for Carbon Monoxide Poisoning
10. Masimo to Report First Quarter 2011 Financial Results After Market Close on May 3, 2011
11. New Published Study Finds Masimo SET® Delivers More Reliable Measurements Significantly Faster Than Other Pulse Oximetry Technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... -- Cardica, Inc. (Nasdaq: CRDC ) today announced that it ... June 30, 2015, on Thursday, August 6, 2015, after the ... 4:30 p.m. Eastern Time to discuss the financial results and ... Conference Call Details To access the live conference call on ... please dial 877-703-6106 from the United States ...
(Date:7/27/2015)... IRVINE, Calif. , July 27, 2015 ... ELOS ) , a global market leader in ... has received Korean Ministry of Food and Drug Safety ... this regulatory clearance, the Company can fulfill PicoWay orders ... activity in Korea anticipated later in the third quarter ...
(Date:7/27/2015)... YORK , July 27, 2015  Relmada ... novel therapies for the treatment of chronic pain, ... Trial Application (CTA) with Heath Canada ... study with d-Methadone (dextromethadone, REL-1017), its novel, N-methyl-D-aspartate ... of neuropathic pain. "We are very ...
Breaking Medicine Technology:Cardica To Announce Fiscal 2015 Fourth Quarter Financial Results On Thursday, August 6, 2015 2Syneron Receives Korean MFDS Regulatory Clearance for PicoWay Picosecond Laser 2Syneron Receives Korean MFDS Regulatory Clearance for PicoWay Picosecond Laser 3Syneron Receives Korean MFDS Regulatory Clearance for PicoWay Picosecond Laser 4Relmada Therapeutics Announces Filing of Clinical Trial Application in Canada for Multiple Ascending Dose Study with Promising NMDA Receptor Antagonist d-Methadone 2Relmada Therapeutics Announces Filing of Clinical Trial Application in Canada for Multiple Ascending Dose Study with Promising NMDA Receptor Antagonist d-Methadone 3
... NEW YORK, June 3 Delcath Systems, Inc.,(Nasdaq: ... Center of,Bethlehem, PA, part of St. Luke,s Hospital & ... trial for the treatment of,inoperable metastatic melanoma in the ... the isolated, high dose,delivery of the anti-cancer agent melphalan. ...
... Data Presented at ASCO Show 26% Partial Response, 63% Clinical Benefit ... ... Calif., June 3 Kosan Biosciences,Incorporated (Nasdaq: KOSN ) today ... antitumor activity in a Phase 2,trial when administered in combination with ...
Cached Medicine Technology:Delcath Expands Phase III Trial for Metastatic Melanoma to Include St. Luke's Cancer Center 2Delcath Expands Phase III Trial for Metastatic Melanoma to Include St. Luke's Cancer Center 3Kosan's Lead Hsp90 Inhibitor, Tanespimycin, Shows High Level of Activity in Trastuzumab Resistant/Refractory HER2-Positive Breast Cancer in a Phase 2 Trial 2Kosan's Lead Hsp90 Inhibitor, Tanespimycin, Shows High Level of Activity in Trastuzumab Resistant/Refractory HER2-Positive Breast Cancer in a Phase 2 Trial 3Kosan's Lead Hsp90 Inhibitor, Tanespimycin, Shows High Level of Activity in Trastuzumab Resistant/Refractory HER2-Positive Breast Cancer in a Phase 2 Trial 4Kosan's Lead Hsp90 Inhibitor, Tanespimycin, Shows High Level of Activity in Trastuzumab Resistant/Refractory HER2-Positive Breast Cancer in a Phase 2 Trial 5Kosan's Lead Hsp90 Inhibitor, Tanespimycin, Shows High Level of Activity in Trastuzumab Resistant/Refractory HER2-Positive Breast Cancer in a Phase 2 Trial 6
(Date:7/28/2015)... ... July 28, 2015 , ... North ... California in the fall of 2015 . These seventeen courses are pre-approved ... , Optimizing Functional Mobility in the Older Adult , August 22, ...
(Date:7/28/2015)... ... July 28, 2015 , ... ... for Invisalign. Invisalign is a revolutionary orthodontic treatment that allows patients to straighten ... Mozafari’s expertise and 3D computer imaging technology. You wear each set of aligners ...
(Date:7/27/2015)... ... 28, 2015 , ... Dr. Robert G. Schwartz , principal of Greenville, ... with Realief Neuropathy Centers in order to offer his patients a new system of ... of peripheral neuropathy. , Peripheral neuropathy is a disease caused by damage to the ...
(Date:7/27/2015)... ... July 28, 2015 , ... Conducting Advanced Root ... to Improve the Quality of Investigations , **Presented by FDAnews and Learning Plus**, ... CAPAs have been the #1 reason for 483 observations since 1997! , The ...
(Date:7/27/2015)... , ... July 28, 2015 , ... The National ... inductee into the NAPW VIP Woman of the Year Circle. She is recognized with ... 200 operating Local Chapters, NAPW is the nation’s leading networking organization exclusively for professional ...
Breaking Medicine News(10 mins):Health News:North American Seminars receives California PT Board approval for Seventeen Continuing Education Courses presented in the Fall of 2015. 2Health News:North American Seminars receives California PT Board approval for Seventeen Continuing Education Courses presented in the Fall of 2015. 3Health News:North American Seminars receives California PT Board approval for Seventeen Continuing Education Courses presented in the Fall of 2015. 4Health News:North American Seminars receives California PT Board approval for Seventeen Continuing Education Courses presented in the Fall of 2015. 5Health News:North American Seminars receives California PT Board approval for Seventeen Continuing Education Courses presented in the Fall of 2015. 6Health News:North American Seminars receives California PT Board approval for Seventeen Continuing Education Courses presented in the Fall of 2015. 7Health News:North American Seminars receives California PT Board approval for Seventeen Continuing Education Courses presented in the Fall of 2015. 8Health News:Cupertino Invisalign Dentist, Dr. Setareh Mozafari, is Now Offering Complimentary Consultations for Invisalign 2Health News:Piedmont Physical Medicine & Rehabilitation, P.A. Partners with Realief® Neuropathy Centers to Offer Peripheral Neuropathy Laser Treatment 2Health News:FDAnews Announces: Conducting Advanced Root Cause Analysis CAPA Investigations, Sept. 16-17, 2015, Raleigh, NC 2Health News:FDAnews Announces: Conducting Advanced Root Cause Analysis CAPA Investigations, Sept. 16-17, 2015, Raleigh, NC 3Health News:FDAnews Announces: Conducting Advanced Root Cause Analysis CAPA Investigations, Sept. 16-17, 2015, Raleigh, NC 4Health News:NAPW Inducts Deana Skidmore, Assistant Director of Nursing at Wilton Meadows Rehablilitation and Health Care Center, Into its VIP Woman of the Year Circle 2
... Still Has No System to Monitor MRSA in ... WASHINGTON, Dec. 3 A new study published ... Emerging Infectious,Diseases links a new strain of methicillin-resistant ... more than 20 percent of all human MRSA,infections ...
... LipoScience, Inc. is pleased to,announce the election of ... Mr. Landon has over 30 years of broad, multi-functional ... management, Mr. Landon,was Vice President & General Manager of ... for all of DuPont,s Medical,Products businesses, with total sales ...
... Neuro Kinetics, Inc., (http://www.neuro-kinetics.com ), manufacturers ... for balance, vestibular and neurological disorder,tests, ... has been appointed clinical director,audiology., ... testing, coordination of multi-,site research projects, ...
... Oncology (ESMO) is calling on European politicians to voice their ... receive the best possible treatment. , At a meeting ... States met in Brussels to consider the status of medical ... Such recognition is an essential step in providing optimal treatment ...
... with stimulants, antidepressants and other psychiatric drugs is ... lack of clinical practice guidelines. In a first ... professionals from the Bradley Hasbro Childrens Research Center ... specific disorders to help clinicians who are considering ...
... beat out college students in tests involving digits 1 through ... -- It may be a case of monkey see, monkey ... human adults at remembering numbers. , A team of Japanese ... had learned how to identify the numbers 1 through 9 ...
Cached Medicine News:Health News:New Study Links Animal Agriculture to More Than 20% of MRSA Infections in the Netherlands 2Health News:Neuro Kinetics Appoints Dr. Terri Ives Clinical Director, Audiology 2Health News:Cancer patients to be treated by qualified professionals 2Health News:Child mental health experts issue psychiatric medication treatment guidelines for preschoolers 2Health News:Child mental health experts issue psychiatric medication treatment guidelines for preschoolers 3Health News:Chimps Top Humans in Number Recall 2
Silicone Elastomer-Coated Latex Foley Catheters 2-Way...
Silicone Foley Catheters 3-Way...
Midstream Catch Kits...
... The BladderScan® BVI 6300 Bladder Monitor ... prescribed by the healthcare provider to ... on an ongoing basis. It is ... accurate results, so the patient can ...
Medicine Products: